N/A
Completed N=6
Duchenne Muscular Dystrophy Clinical Trial
Source: ClinicalTrials.gov NCT01874275 ↗Enrolled (actual)
6
Serious AEs
—
Results posted
Mar 2015
Primary outcomePrimary: Percent Change in Range of Motion From Baseline to 180 Days — 67; 33 percentage of change
Summary
The primary objective of this investigation is to assess the effectiveness of transcutaneous electrical nerve stimulation applied using VECTTOR to reduce the symptoms of Duchenne Muscular Dystrophy and reduce the impact of DMD upon the participants' quality of life.
The primary outcome measures will include:
1. increased muscle strength,
2. increased range of joint motions and
3. improved sleep parameters of ASI, N3 and REM.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Range of Motion From Baseline to 180 Days |
67; 33 | — |
| SECONDARY Percent Change in Muscle Strength |
110 | — |
| SECONDARY Percent Change in Percent Range of Motion From Baseline to 365 Days |
59 | — |
Eligibility Criteria
Inclusion Criteria
- Participants must have Duchenne Muscular Dystrophy diagnosis as confirmed by licensed physician, wheelchair bound, & age 8 - 20 years old.
Exclusion Criteria
- Active cancer in the area of application of the treatment, infection, skin infection, pregnancy, thrombophlebitis, pacemaker, amputation of any part of feet or hands, taking steroids. In addition, the participant may not be in any other clinical trial during the time they are in this study.
Data sourced from ClinicalTrials.gov (NCT01874275). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.